Trading Options with an Edge
Select Page

ALDX

Search by
TICKER SYMBOL

Aldeyra Therapeutics Inc

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing

7.97

-0.02

(-0.25%)

Volume:

238,779

52 week range:

6.21 - 15.95

Market Cap:

461.176M

Company Description:

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer.